Howard Stern TRT: What It Would Cost a Non-Celebrity

What Howard Stern Has Said About TRT

Howard Stern has referenced testosterone replacement therapy multiple times on The Howard Stern Show. He has not published a detailed medical protocol, but his on-air comments confirm that he uses some form of testosterone therapy and considers it part of his health maintenance routine as he ages. Stern, born in 1954, falls squarely in the demographic most commonly prescribed TRT.

Public Statements vs. Protocol Details

Stern's openness about TRT stands out among public figures, though his disclosures remain general. He has mentioned TRT in the context of energy, mood, and aging. He has not specified his dose, formulation, or prescribing physician on air. Any protocol details beyond his confirmed use are inference, and this article labels them as such.

Why Celebrity TRT Disclosure Matters

When a figure with Stern's audience size discusses hormone therapy, it moves the treatment out of niche men's health forums and into mainstream conversation. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism notes that patient education and shared decision-making are central to appropriate TRT use [1]. Public discussion, even partial, supports that goal.

The Clinical Basis for TRT

Testosterone replacement therapy is FDA-approved for men with clinical hypogonadism, defined by the Endocrine Society as consistently low serum testosterone (total T <300 ng/dL) combined with signs or symptoms such as reduced libido, fatigue, loss of muscle mass, or depressed mood [1]. TRT is not approved for age-related testosterone decline alone, though prescribing patterns show significant off-label use.

Prevalence of Low Testosterone

A 2006 study published in the International Journal of Clinical Practice estimated that hypogonadism affects roughly 38.7% of men aged 45 and older who present to primary care, with rates climbing higher among men with obesity or type 2 diabetes [2]. The Massachusetts Male Aging Study found that total testosterone declines by approximately 1.6% per year after age 40 [3]. For a man in his early 70s, like Stern, physiologic testosterone production may sit well below the levels of his younger years.

When TRT Is Appropriate

The American Urological Association (AUA) recommends TRT for men with a total testosterone level below 300 ng/dL confirmed on at least two early-morning measurements, along with clinical symptoms [4]. The AUA guideline explicitly states: "Clinicians should inform testosterone deficient patients of the benefits and risks of testosterone therapy and should counsel patients that the evidence regarding the long-term benefits and safety is not established" [4]. That framing matters for any patient, celebrity or otherwise, weighing TRT.

What a Stern-Like TRT Protocol Probably Looks Like

Since Stern has not disclosed his specific regimen, the following represents a reasonable clinical estimate based on his age, sex, and the most commonly prescribed TRT protocols for men in their late 60s and 70s. This is inference, not confirmed information.

Most Likely Formulation

Testosterone cypionate by intramuscular or subcutaneous injection is the most widely prescribed TRT formulation in the United States. It is available as a generic, it is dosed easily, and it provides stable serum levels with injections every 1 to 2 weeks. A typical starting dose is 100 mg weekly or 200 mg every two weeks, adjusted based on trough testosterone levels and symptom response [1].

Possible Alternatives

A patient with Stern's resources might opt for a transdermal gel (AndroGel, Testim), a nasal formulation (Natesto), or the oral capsule Jatenzo. These carry a significant price premium over generic injectable testosterone. An underarm solution (Axiron) and subcutaneous pellets (Testopel) are additional options. The choice depends on lifestyle, needle comfort, and absorption consistency.

Ancillary Medications

Some TRT protocols include an aromatase inhibitor (anastrozole) to manage estradiol conversion, or human chorionic gonadotropin (hCG) for testicular volume preservation and fertility. The Endocrine Society guideline advises against routine anastrozole use with TRT, recommending dose adjustment as the first-line approach for elevated estradiol [1]. HCG is typically reserved for men who wish to preserve fertility, which is less common in Stern's age group.

Breaking Down the Cost: Medication

This is the number a non-celebrity patient cares about most. TRT medication costs vary by formulation, pharmacy, and insurance status.

Generic Testosterone Cypionate (Injectable)

A 10 mL vial of testosterone cypionate 200 mg/mL, which lasts approximately 10 to 20 weeks depending on dose, costs $30 to $90 at most retail pharmacies using a GoodRx-style discount card [5]. That translates to roughly $80 to $250 per year for the medication itself. Syringes and alcohol swabs add $20 to $50 annually. This is the most affordable TRT path.

Brand-Name Gels

AndroGel 1.62% carries a list price exceeding $500 per month. Even with manufacturer coupons, patients often pay $75 to $200 per month. Annual cost: $900 to $6,000 depending on coverage. A study in the Journal of Sexual Medicine found that transdermal formulations had higher discontinuation rates partly due to cost and skin-transfer concerns [6].

Oral and Nasal Options

Jatenzo (oral testosterone undecanoate) carries a wholesale acquisition cost of roughly $500 per month. Natesto nasal gel runs $200 to $600 per month. Neither has a generic equivalent as of 2026. These formulations suit patients who refuse injections and dislike topical gels, but the price gap is steep.

Compounded Testosterone

Compounded testosterone cream or injectable from a 503A or 503B pharmacy typically costs $40 to $100 per month. Quality and consistency vary by pharmacy. The FDA has raised concerns about compounded hormone products, noting that they do not undergo the same approval process as commercially manufactured drugs [7].

Breaking Down the Cost: Monitoring and Physician Visits

Medication cost alone is misleading. TRT requires regular bloodwork and clinical oversight.

Required Baseline Labs

Before starting TRT, clinicians order baseline testosterone (two morning draws), complete blood count (CBC), comprehensive metabolic panel, lipid panel, PSA, and sometimes a DEXA scan or LH/FSH levels. Out of pocket, this panel runs $200 to $500 through direct-pay lab services. Insurance typically covers it with a diagnosis code for hypogonadism (ICD-10 E29.1).

Ongoing Monitoring Schedule

The Endocrine Society recommends checking testosterone levels 3 to 6 months after starting therapy, then annually once stable [1]. CBC should be monitored at 3 to 6 months and then annually because TRT raises hematocrit. PSA testing is recommended at 3 to 6 months and annually for men over 40. A 2010 meta-analysis in BMC Medicine including 51 studies and over 3,400 men found that TRT was associated with a modest increase in hematocrit, reinforcing the need for monitoring [8].

Annual Monitoring Cost Estimate

Two to four lab panels per year at $100 to $200 each: $200 to $800. Two to four physician visits (in-person or telehealth) at $75 to $200 each: $150 to $800. Total monitoring cost range: $350 to $1,600 annually. Many insurance plans cover the majority of this once hypogonadism is diagnosed.

The Telehealth Clinic Model

A growing segment of TRT patients bypass traditional endocrinology and urology offices in favor of men's health telehealth platforms.

How Telehealth TRT Works

Platforms like these typically bundle the consultation, lab orders, medication (shipped to the patient), and ongoing monitoring into a monthly subscription. Prices range from $100 to $250 per month. Some clinics include anastrozole, hCG, or DHEA supplements in their protocol. Convenience is high. The trade-off is that bundled pricing sometimes exceeds what a patient would pay assembling the same protocol through insurance and a retail pharmacy.

Cost Comparison: Telehealth vs. Traditional

For an insured patient with a $30 specialist copay and generic testosterone cypionate on formulary, the annual cost could be as low as $300 to $600 total. For an uninsured patient using a telehealth subscription at $150 per month, the annual cost reaches $1,800. The gap narrows for patients using brand-name formulations, where telehealth platforms may offer competitive pricing through compounding partnerships.

Choosing Between Models

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society TRT guideline, has noted: "Testosterone therapy requires thoughtful monitoring and dose adjustments. The prescribing physician should have experience managing hypogonadism and its complications" [1]. That statement applies regardless of whether the provider works in a brick-and-mortar clinic or a telehealth platform.

Insurance Coverage for TRT

Insurance is the single largest variable in TRT affordability. Coverage patterns differ sharply between plan types.

Commercial Insurance

Most commercial plans cover generic testosterone cypionate with a prior authorization confirming two low testosterone levels and documented symptoms. Copays for a 90-day supply of generic injectable testosterone sit in the $10 to $45 range on most formularies. Brand-name gels and newer formulations often require step therapy (fail generics first) or sit on higher formulary tiers.

Medicare

Medicare Part D covers testosterone cypionate and enanthate as generic injectables. Part B covers injectable testosterone administered in a physician's office. A 2017 analysis in JAMA Internal Medicine found that testosterone prescribing among Medicare beneficiaries increased substantially between 2007 and 2014, though it declined after the FDA's 2015 label revision requiring cardiovascular risk warnings [9]. Out-of-pocket costs for Medicare patients using generic injectables are typically minimal after meeting the deductible.

The FDA Label Change

In 2015, the FDA required testosterone product labeling to include a warning about possible increased cardiovascular risk and restricted the approved indication to men with hypogonadism due to identifiable conditions (disorders of the testes, pituitary, or hypothalamus), not age-related decline alone [10]. This label change affects insurance prior authorization criteria. Plans increasingly require documentation of an organic cause, not just a low number.

What This Means for Affordability

Patients with clearly documented hypogonadism from a testicular, pituitary, or hypothalamic cause face fewer insurance barriers. Men with borderline-low testosterone and nonspecific symptoms (the "Low T" marketing demographic) may find coverage harder to obtain, pushing them toward cash-pay clinics or telehealth subscriptions.

Total Annual Cost: The Real Number

Assembling all components, here is what a non-celebrity patient can expect.

Best Case: Insured, Generic Injectable

• Medication: $40 to $150/year (generic cypionate, insurance copay)
• Labs: $50 to $200/year (insurance-covered with copay)
• Physician visits: $60 to $240/year (2 to 4 visits at $30 copay)
• Total: $150 to $590/year

Mid Case: Uninsured, Generic Injectable, Direct-Pay Labs

• Medication: $80 to $250/year
• Labs: $200 to $600/year
• Physician visits: $200 to $500/year (telehealth or direct primary care)
• Total: $480 to $1,350/year

High Case: Telehealth Subscription or Brand-Name Formulation

• Bundled subscription: $1,200 to $3,000/year
• Or brand-name gel without insurance: $2,400 to $6,000/year for medication alone
• Labs and visits often included in subscription; add $300 to $800 if not
• Total: $1,200 to $6,800/year

For context, Howard Stern's estimated annual income exceeds $90 million from his SiriusXM contract. Even the most expensive TRT protocol represents a negligible fraction of his resources. For the median American household earning roughly $75,000, the mid-case scenario consumes about 1% of gross income.

What Stern's Openness Does for the Conversation

Celebrity disclosure of TRT use normalizes a treatment that still carries stigma. The T Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, found that one year of testosterone gel improved sexual function, walking distance, and mood compared to placebo [11]. Those are real, measurable outcomes. Public figures confirming that they pursue TRT for similar benefits may encourage men with genuine hypogonadism to seek evaluation rather than dismiss symptoms as normal aging.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided important safety data: testosterone replacement in men aged 45 to 80 with hypogonadism and cardiovascular risk factors did not increase the incidence of major adverse cardiac events compared to placebo over a mean follow-up of 33 months [12]. That finding reshaped the risk-benefit discussion for older men considering TRT.

The most useful thing Stern could do, clinically speaking, is encourage his listeners to get their levels checked with two morning blood draws before starting any protocol. A single afternoon testosterone measurement is unreliable due to diurnal variation and can lead to unnecessary treatment or false reassurance.